Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,437,712.18. This represents a 23.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Trading Down 0.2 %

Shares of UTHR traded down $0.46 during mid-day trading on Friday, hitting $284.73. The company’s stock had a trading volume of 302,945 shares, compared to its average volume of 453,066. The firm has a market capitalization of $12.79 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 0.97 and a beta of 0.63. The company’s 50-day moving average is $317.98 and its 200-day moving average is $349.16. United Therapeutics Co. has a 52-week low of $233.28 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period last year, the business posted $4.36 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics in the 4th quarter worth $25,000. Dunhill Financial LLC raised its holdings in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after buying an additional 50 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $49,000. State of Wyoming acquired a new position in shares of United Therapeutics in the 4th quarter valued at $62,000. Finally, Curat Global LLC acquired a new stake in United Therapeutics during the 1st quarter worth about $63,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.